PharmaCyte Biotech, Inc. (PMCB) - 10-K Summary
Business Context and Reporting Period
Company: PharmaCyte Biotech, Inc.
Filing Type: Form 10-K (Annual Report)
Fiscal Year Ended: April 30, 2025
Business Overview: A biotechnology company developing cellular therapies for cancer using proprietary "Cell-in-a-Box" technology. The primary focus is a product candidate (CypCaps) for locally advanced, inoperable, non-metastatic pancreatic cancer (LAPC).
Operational Status: The company has no commercial revenue. Operations are focused on addressing an FDA clinical hold placed on its Investigational New Drug (IND) application in October 2020. Spending on development programs has been curtailed pending a review by the Board and Strategic Scientific Committee regarding the company's relationship with its technology licensor, SG Austria.
Key Financial Metrics
| Metric | Fiscal Year 2025 | Fiscal Year 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Income (Loss) | $30,656,050 | $333,763 |
| Net Income Attributable to Common Stockholders | $23,362,107 | $(17,237,403) |
| Operating Expenses | $4,377,862 | $8,520,008 |
| Cash and Cash Equivalents (End of Period) | $15,172,163 | $50,179,968 |
| Working Capital | $19,460,954 | $43,018,504 |
| Accumulated Deficit | $(84,968,960) | $(115,625,010) |
Note: The reported Net Income for 2025 is primarily driven by non-operating gains, including a $21.4 million gain on a related-party investment in TNF Pharmaceuticals and changes in the fair value of financial instruments. Operating expenses decreased significantly year-over-year due to reduced spending on development programs.
Material Changes vs. Prior Period
- Investment Activity: The company invested $7.0 million in TNF Pharmaceuticals, Inc. (Series G Preferred Stock and warrants) in FY2025, compared to a $5.0 million investment in Femasys, Inc. in FY2024.
- Stock Repurchases: The company repurchased 1,241,862 shares of common stock for approximately $2.54 million in FY2025, compared to $28.2 million in repurchases in FY2024.
- Preferred Stock Redemption: All Series B Convertible Preferred Stock was redeemed in FY2025, eliminating the associated dividend obligations and accretion costs present in FY2024.
- Legal Settlement: A $2.02 million legal settlement expense was recorded in FY2025 related to a breach of contract claim with H.C. Wainwright & Co., LLC.
- Asset Impairment: No impairment was recorded in FY2025, compared to a $2.0 million impairment of a diabetes license asset in FY2024.
Guidance, Outlook, and Risks
Outlook and Management Commentary: Management expects current cash balances to fund operations for at least the next 12 months. The primary strategic objective remains lifting the FDA clinical hold on the LAPC trial. The company is in active dialogue with the FDA to potentially forego a large animal study, arguing that existing human clinical trial data supersedes it. However, the FDA may still require additional preclinical studies. The Board is reviewing the relationship with SG Austria, noting that all licensed patents have expired and know-how resides solely with SG Austria.
Key Risks and Contingencies:
- FDA Clinical Hold: The IND remains on clinical hold since October 2020. Failure to lift the hold would likely terminate clinical development plans.
- Third-Party Dependence: The company relies entirely on Austrianova (a subsidiary of SG Austria) for manufacturing. Austrianova has experienced supply chain delays and potential liquidity issues.
- Liquidity: The company has a history of operating losses and will require additional capital to complete clinical trials. Future financing may be dilutive or restrictive.
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting, specifically regarding insufficient segregation of duties and management review controls.
- Intellectual Property: Foundational patents licensed from Bavarian Nordic/GSF expired in 2017. The company relies on trade secrets and pending applications for future protection.
Investor Verification Checklist
- FDA Status: Verify the current status of the clinical hold and any recent correspondence or meeting outcomes with the FDA regarding the LAPC trial.
- SG Austria Relationship: Confirm the outcome of the Board's review of the relationship with SG Austria and whether a new framework or alternative manufacturing source has been secured.
- Cash Runway: Assess the burn rate and confirm the timeline for the next potential capital raise given the $15.2 million cash balance.
- Investment Valuation: Review the valuation methodology and fair value assumptions for the TNF Pharmaceuticals investment, which drove the majority of the FY2025 net income.
- Internal Controls: Monitor progress on remediation plans for the identified material weaknesses in internal controls over financial reporting.